ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antibacterial (Drug) Resistance Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-3D8830
Home | Market Reports | Health| Pharmacy
Global Antibacterial Drug Resistance Market Insights and Forecast to 2028
BUY CHAPTERS

Global Antibacterial (Drug) Resistance Market Research Report 2025

Code: QYRE-Auto-3D8830
Report
September 2025
Pages:123
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Melinta Therapeutics
Allergan plc
Merck
Abbott Laboratories
Pfizer Inc
GSK
Pendopharm
Absynth Biologics
Achaogen Inc
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO

Antibacterial (Drug) Resistance Market Size

The global market for Antibacterial (Drug) Resistance was valued at US$ 9020 million in the year 2024 and is projected to reach a revised size of US$ 12880 million by 2031, growing at a CAGR of 5.3% during the forecast period.

Antibacterial (Drug) Resistance Market

Antibacterial (Drug) Resistance Market

Antibacterial drug resistance is the process that bacteria use to tolerate and overcome the effects of antibiotic drugs. Resistance can arise through mutations or can be acquired from other bacteria through plasmids.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Antibacterial (Drug) Resistance, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibacterial (Drug) Resistance.
The Antibacterial (Drug) Resistance market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibacterial (Drug) Resistance market comprehensively. Regional market sizes, concerning products by Type, by Indication, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibacterial (Drug) Resistance manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Indication, and by regions.

Scope of Antibacterial (Drug) Resistance Market Report

Report Metric Details
Report Name Antibacterial (Drug) Resistance Market
Accounted market size in year US$ 9020 million
Forecasted market size in 2031 US$ 12880 million
CAGR 5.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Telavancin (Vibativ)
  • Ceftaroline Fosamil (Teflaro/ Zinforo)
  • Fidaxomicin (Dificid / Dificlir)
  • Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  • Dalbavancin (Dalvance/ Xydalba)
  • Tedizolid Phosphate (Sivextro)
  • Oritavancin (Orbactiv/ Nuvocid)
  • Ceftolozane-Tazobactam (Zerbaxa)
  • Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  • PHASE III DRUGS
Segment by Indication
  • Complicated Urinary Tract Infection (CUTI)
  • Complicated Intra-Abdominal Infections (CIAI)
  • Blood Stream Infections (BSI)
  • Clostridium Difficile Infections (CDI)
  • Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • Community Acquired Bacterial Pneumonia (CABP)
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Melinta Therapeutics, Allergan, Merck, Abbott Laboratories, Pfizer, GSK, PENDOPHARM, Absynth Biologics, Achaogen, Acino Holdings, Aventis Pharma, Austell Laboratories, Assembly Biosciences, Arpida, Demuris, Evolva Holding, ContraFect, Cerexa, InterMune, Isis Pharmaceuticals, Lyndra, Microbecide, Morphochem, Nabriva Therapeutics, NanoSafe Coatings, Novexel, Osel, VenatoRx Pharmaceuticals, AAIPharma Services, ANTABIO
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Antibacterial (Drug) Resistance manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Antibacterial (Drug) Resistance in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Indication, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Antibacterial (Drug) Resistance Market growing?

Ans: The Antibacterial (Drug) Resistance Market witnessing a CAGR of 5.3% during the forecast period 2025-2031.

What is the Antibacterial (Drug) Resistance Market size in 2031?

Ans: The Antibacterial (Drug) Resistance Market size in 2031 will be US$ 12880 million.

Who are the main players in the Antibacterial (Drug) Resistance Market report?

Ans: The main players in the Antibacterial (Drug) Resistance Market are Melinta Therapeutics, Allergan, Merck, Abbott Laboratories, Pfizer, GSK, PENDOPHARM, Absynth Biologics, Achaogen, Acino Holdings, Aventis Pharma, Austell Laboratories, Assembly Biosciences, Arpida, Demuris, Evolva Holding, ContraFect, Cerexa, InterMune, Isis Pharmaceuticals, Lyndra, Microbecide, Morphochem, Nabriva Therapeutics, NanoSafe Coatings, Novexel, Osel, VenatoRx Pharmaceuticals, AAIPharma Services, ANTABIO

What are the Type segmentation covered in the Antibacterial (Drug) Resistance Market report?

Ans: The Types covered in the Antibacterial (Drug) Resistance Market report are Telavancin (Vibativ), Ceftaroline Fosamil (Teflaro/ Zinforo), Fidaxomicin (Dificid / Dificlir), Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio), Dalbavancin (Dalvance/ Xydalba), Tedizolid Phosphate (Sivextro), Oritavancin (Orbactiv/ Nuvocid), Ceftolozane-Tazobactam (Zerbaxa), Ceftazidime-Avibactam (Avycaz/ Zavicefta), PHASE III DRUGS

1 Antibacterial (Drug) Resistance Market Overview
1.1 Product Definition
1.2 Antibacterial (Drug) Resistance by Type
1.2.1 Global Antibacterial (Drug) Resistance Market Value Comparison by Type (2024 VS 2031)
1.2.2 Telavancin (Vibativ)
1.2.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
1.2.4 Fidaxomicin (Dificid / Dificlir)
1.2.5 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
1.2.6 Dalbavancin (Dalvance/ Xydalba)
1.2.7 Tedizolid Phosphate (Sivextro)
1.2.8 Oritavancin (Orbactiv/ Nuvocid)
1.2.9 Ceftolozane-Tazobactam (Zerbaxa)
1.2.10 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
1.3 Antibacterial (Drug) Resistance by Indication
1.3.1 Global Antibacterial (Drug) Resistance Market Value by Indication (2024 VS 2031)
1.3.2 Complicated Urinary Tract Infection (CUTI)
1.3.3 Complicated Intra-Abdominal Infections (CIAI)
1.3.4 Blood Stream Infections (BSI)
1.3.5 Clostridium Difficile Infections (CDI)
1.3.6 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
1.3.7 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
1.3.8 Community Acquired Bacterial Pneumonia (CABP)
1.4 Global Antibacterial (Drug) Resistance Market Size Estimates and Forecasts
1.4.1 Global Antibacterial (Drug) Resistance Revenue 2020-2031
1.4.2 Global Antibacterial (Drug) Resistance Sales 2020-2031
1.4.3 Global Antibacterial (Drug) Resistance Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Antibacterial (Drug) Resistance Market Competition by Manufacturers
2.1 Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturers (2020-2025)
2.2 Global Antibacterial (Drug) Resistance Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Antibacterial (Drug) Resistance Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Antibacterial (Drug) Resistance, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antibacterial (Drug) Resistance, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antibacterial (Drug) Resistance, Product Type & Application
2.7 Global Key Manufacturers of Antibacterial (Drug) Resistance, Date of Enter into This Industry
2.8 Global Antibacterial (Drug) Resistance Market Competitive Situation and Trends
2.8.1 Global Antibacterial (Drug) Resistance Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Antibacterial (Drug) Resistance Players Market Share by Revenue
2.8.3 Global Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antibacterial (Drug) Resistance Market Scenario by Region
3.1 Global Antibacterial (Drug) Resistance Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Antibacterial (Drug) Resistance Sales by Region: 2020-2031
3.2.1 Global Antibacterial (Drug) Resistance Sales by Region: 2020-2025
3.2.2 Global Antibacterial (Drug) Resistance Sales by Region: 2026-2031
3.3 Global Antibacterial (Drug) Resistance Revenue by Region: 2020-2031
3.3.1 Global Antibacterial (Drug) Resistance Revenue by Region: 2020-2025
3.3.2 Global Antibacterial (Drug) Resistance Revenue by Region: 2026-2031
3.4 North America Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.4.1 North America Antibacterial (Drug) Resistance Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Antibacterial (Drug) Resistance Sales by Country (2020-2031)
3.4.3 North America Antibacterial (Drug) Resistance Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.5.1 Europe Antibacterial (Drug) Resistance Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Antibacterial (Drug) Resistance Sales by Country (2020-2031)
3.5.3 Europe Antibacterial (Drug) Resistance Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antibacterial (Drug) Resistance Market Facts & Figures by Region
3.6.1 Asia Pacific Antibacterial (Drug) Resistance Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2020-2031)
3.6.3 Asia Pacific Antibacterial (Drug) Resistance Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.7.1 Latin America Antibacterial (Drug) Resistance Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Antibacterial (Drug) Resistance Sales by Country (2020-2031)
3.7.3 Latin America Antibacterial (Drug) Resistance Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antibacterial (Drug) Resistance Market Facts & Figures by Country
3.8.1 Middle East and Africa Antibacterial (Drug) Resistance Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2020-2031)
3.8.3 Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antibacterial (Drug) Resistance Sales by Type (2020-2031)
4.1.1 Global Antibacterial (Drug) Resistance Sales by Type (2020-2025)
4.1.2 Global Antibacterial (Drug) Resistance Sales by Type (2026-2031)
4.1.3 Global Antibacterial (Drug) Resistance Sales Market Share by Type (2020-2031)
4.2 Global Antibacterial (Drug) Resistance Revenue by Type (2020-2031)
4.2.1 Global Antibacterial (Drug) Resistance Revenue by Type (2020-2025)
4.2.2 Global Antibacterial (Drug) Resistance Revenue by Type (2026-2031)
4.2.3 Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2020-2031)
4.3 Global Antibacterial (Drug) Resistance Price by Type (2020-2031)
5 Segment by Indication
5.1 Global Antibacterial (Drug) Resistance Sales by Indication (2020-2031)
5.1.1 Global Antibacterial (Drug) Resistance Sales by Indication (2020-2025)
5.1.2 Global Antibacterial (Drug) Resistance Sales by Indication (2026-2031)
5.1.3 Global Antibacterial (Drug) Resistance Sales Market Share by Indication (2020-2031)
5.2 Global Antibacterial (Drug) Resistance Revenue by Indication (2020-2031)
5.2.1 Global Antibacterial (Drug) Resistance Revenue by Indication (2020-2025)
5.2.2 Global Antibacterial (Drug) Resistance Revenue by Indication (2026-2031)
5.2.3 Global Antibacterial (Drug) Resistance Revenue Market Share by Indication (2020-2031)
5.3 Global Antibacterial (Drug) Resistance Price by Indication (2020-2031)
6 Key Companies Profiled
6.1 Melinta Therapeutics
6.1.1 Melinta Therapeutics Company Information
6.1.2 Melinta Therapeutics Description and Business Overview
6.1.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio
6.1.5 Melinta Therapeutics Recent Developments/Updates
6.2 Allergan
6.2.1 Allergan Company Information
6.2.2 Allergan Description and Business Overview
6.2.3 Allergan Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Allergan Antibacterial (Drug) Resistance Product Portfolio
6.2.5 Allergan Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck Antibacterial (Drug) Resistance Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Abbott Laboratories
6.4.1 Abbott Laboratories Company Information
6.4.2 Abbott Laboratories Description and Business Overview
6.4.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio
6.4.5 Abbott Laboratories Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Antibacterial (Drug) Resistance Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 GSK
6.6.1 GSK Company Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.6.4 GSK Antibacterial (Drug) Resistance Product Portfolio
6.6.5 GSK Recent Developments/Updates
6.7 PENDOPHARM
6.7.1 PENDOPHARM Company Information
6.7.2 PENDOPHARM Description and Business Overview
6.7.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.7.4 PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio
6.7.5 PENDOPHARM Recent Developments/Updates
6.8 Absynth Biologics
6.8.1 Absynth Biologics Company Information
6.8.2 Absynth Biologics Description and Business Overview
6.8.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio
6.8.5 Absynth Biologics Recent Developments/Updates
6.9 Achaogen
6.9.1 Achaogen Company Information
6.9.2 Achaogen Description and Business Overview
6.9.3 Achaogen Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Achaogen Antibacterial (Drug) Resistance Product Portfolio
6.9.5 Achaogen Recent Developments/Updates
6.10 Acino Holdings
6.10.1 Acino Holdings Company Information
6.10.2 Acino Holdings Description and Business Overview
6.10.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Acino Holdings Antibacterial (Drug) Resistance Product Portfolio
6.10.5 Acino Holdings Recent Developments/Updates
6.11 Aventis Pharma
6.11.1 Aventis Pharma Company Information
6.11.2 Aventis Pharma Description and Business Overview
6.11.3 Aventis Pharma Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio
6.11.5 Aventis Pharma Recent Developments/Updates
6.12 Austell Laboratories
6.12.1 Austell Laboratories Company Information
6.12.2 Austell Laboratories Description and Business Overview
6.12.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio
6.12.5 Austell Laboratories Recent Developments/Updates
6.13 Assembly Biosciences
6.13.1 Assembly Biosciences Company Information
6.13.2 Assembly Biosciences Description and Business Overview
6.13.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio
6.13.5 Assembly Biosciences Recent Developments/Updates
6.14 Arpida
6.14.1 Arpida Company Information
6.14.2 Arpida Description and Business Overview
6.14.3 Arpida Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Arpida Antibacterial (Drug) Resistance Product Portfolio
6.14.5 Arpida Recent Developments/Updates
6.15 Demuris
6.15.1 Demuris Company Information
6.15.2 Demuris Description and Business Overview
6.15.3 Demuris Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Demuris Antibacterial (Drug) Resistance Product Portfolio
6.15.5 Demuris Recent Developments/Updates
6.16 Evolva Holding
6.16.1 Evolva Holding Company Information
6.16.2 Evolva Holding Description and Business Overview
6.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Evolva Holding Antibacterial (Drug) Resistance Product Portfolio
6.16.5 Evolva Holding Recent Developments/Updates
6.17 ContraFect
6.17.1 ContraFect Company Information
6.17.2 ContraFect Description and Business Overview
6.17.3 ContraFect Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.17.4 ContraFect Antibacterial (Drug) Resistance Product Portfolio
6.17.5 ContraFect Recent Developments/Updates
6.18 Cerexa
6.18.1 Cerexa Company Information
6.18.2 Cerexa Description and Business Overview
6.18.3 Cerexa Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Cerexa Antibacterial (Drug) Resistance Product Portfolio
6.18.5 Cerexa Recent Developments/Updates
6.19 InterMune
6.19.1 InterMune Company Information
6.19.2 InterMune Description and Business Overview
6.19.3 InterMune Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.19.4 InterMune Antibacterial (Drug) Resistance Product Portfolio
6.19.5 InterMune Recent Developments/Updates
6.20 Isis Pharmaceuticals
6.20.1 Isis Pharmaceuticals Company Information
6.20.2 Isis Pharmaceuticals Description and Business Overview
6.20.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
6.20.5 Isis Pharmaceuticals Recent Developments/Updates
6.21 Lyndra
6.21.1 Lyndra Company Information
6.21.2 Lyndra Description and Business Overview
6.21.3 Lyndra Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Lyndra Antibacterial (Drug) Resistance Product Portfolio
6.21.5 Lyndra Recent Developments/Updates
6.22 Microbecide
6.22.1 Microbecide Company Information
6.22.2 Microbecide Description and Business Overview
6.22.3 Microbecide Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.22.4 Microbecide Antibacterial (Drug) Resistance Product Portfolio
6.22.5 Microbecide Recent Developments/Updates
6.23 Morphochem
6.23.1 Morphochem Company Information
6.23.2 Morphochem Description and Business Overview
6.23.3 Morphochem Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.23.4 Morphochem Antibacterial (Drug) Resistance Product Portfolio
6.23.5 Morphochem Recent Developments/Updates
6.24 Nabriva Therapeutics
6.24.1 Nabriva Therapeutics Company Information
6.24.2 Nabriva Therapeutics Description and Business Overview
6.24.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.24.4 Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio
6.24.5 Nabriva Therapeutics Recent Developments/Updates
6.25 NanoSafe Coatings
6.25.1 NanoSafe Coatings Company Information
6.25.2 NanoSafe Coatings Description and Business Overview
6.25.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.25.4 NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio
6.25.5 NanoSafe Coatings Recent Developments/Updates
6.26 Novexel
6.26.1 Novexel Company Information
6.26.2 Novexel Description and Business Overview
6.26.3 Novexel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.26.4 Novexel Antibacterial (Drug) Resistance Product Portfolio
6.26.5 Novexel Recent Developments/Updates
6.27 Osel
6.27.1 Osel Company Information
6.27.2 Osel Description and Business Overview
6.27.3 Osel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.27.4 Osel Antibacterial (Drug) Resistance Product Portfolio
6.27.5 Osel Recent Developments/Updates
6.28 VenatoRx Pharmaceuticals
6.28.1 VenatoRx Pharmaceuticals Company Information
6.28.2 VenatoRx Pharmaceuticals Description and Business Overview
6.28.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.28.4 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
6.28.5 VenatoRx Pharmaceuticals Recent Developments/Updates
6.29 AAIPharma Services
6.29.1 AAIPharma Services Company Information
6.29.2 AAIPharma Services Description and Business Overview
6.29.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.29.4 AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio
6.29.5 AAIPharma Services Recent Developments/Updates
6.30 ANTABIO
6.30.1 ANTABIO Company Information
6.30.2 ANTABIO Description and Business Overview
6.30.3 ANTABIO Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2020-2025)
6.30.4 ANTABIO Antibacterial (Drug) Resistance Product Portfolio
6.30.5 ANTABIO Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antibacterial (Drug) Resistance Industry Chain Analysis
7.2 Antibacterial (Drug) Resistance Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antibacterial (Drug) Resistance Production Mode & Process Analysis
7.4 Antibacterial (Drug) Resistance Sales and Marketing
7.4.1 Antibacterial (Drug) Resistance Sales Channels
7.4.2 Antibacterial (Drug) Resistance Distributors
7.5 Antibacterial (Drug) Resistance Customer Analysis
8 Antibacterial (Drug) Resistance Market Dynamics
8.1 Antibacterial (Drug) Resistance Industry Trends
8.2 Antibacterial (Drug) Resistance Market Drivers
8.3 Antibacterial (Drug) Resistance Market Challenges
8.4 Antibacterial (Drug) Resistance Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Melinta Therapeutics
Allergan plc
Merck
Abbott Laboratories
Pfizer Inc
GSK
Pendopharm
Absynth Biologics
Achaogen Inc
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO
List of Tables
 Table 1. Global Antibacterial (Drug) Resistance Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Antibacterial (Drug) Resistance Market Value by Indication (2024 VS 2031) & (US$ Million)
 Table 3. Global Antibacterial (Drug) Resistance Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Antibacterial (Drug) Resistance Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Antibacterial (Drug) Resistance Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Antibacterial (Drug) Resistance Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Antibacterial (Drug) Resistance, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Antibacterial (Drug) Resistance, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Antibacterial (Drug) Resistance, Product Type & Application
 Table 12. Global Key Manufacturers of Antibacterial (Drug) Resistance, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Antibacterial (Drug) Resistance by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibacterial (Drug) Resistance as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Antibacterial (Drug) Resistance Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Antibacterial (Drug) Resistance Sales by Region (2020-2025) & (K Units)
 Table 18. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2020-2025)
 Table 19. Global Antibacterial (Drug) Resistance Sales by Region (2026-2031) & (K Units)
 Table 20. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2026-2031)
 Table 21. Global Antibacterial (Drug) Resistance Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2020-2025)
 Table 23. Global Antibacterial (Drug) Resistance Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2026-2031)
 Table 25. North America Antibacterial (Drug) Resistance Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Antibacterial (Drug) Resistance Sales by Country (2020-2025) & (K Units)
 Table 27. North America Antibacterial (Drug) Resistance Sales by Country (2026-2031) & (K Units)
 Table 28. North America Antibacterial (Drug) Resistance Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Antibacterial (Drug) Resistance Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Antibacterial (Drug) Resistance Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Antibacterial (Drug) Resistance Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Antibacterial (Drug) Resistance Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Antibacterial (Drug) Resistance Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Antibacterial (Drug) Resistance Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Antibacterial (Drug) Resistance Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Antibacterial (Drug) Resistance Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Antibacterial (Drug) Resistance Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Antibacterial (Drug) Resistance Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Antibacterial (Drug) Resistance Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Antibacterial (Drug) Resistance Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Antibacterial (Drug) Resistance Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Antibacterial (Drug) Resistance Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Antibacterial (Drug) Resistance Sales (K Units) by Type (2020-2025)
 Table 51. Global Antibacterial (Drug) Resistance Sales (K Units) by Type (2026-2031)
 Table 52. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2020-2025)
 Table 53. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2026-2031)
 Table 54. Global Antibacterial (Drug) Resistance Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Antibacterial (Drug) Resistance Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2020-2025)
 Table 57. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2026-2031)
 Table 58. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Antibacterial (Drug) Resistance Sales (K Units) by Indication (2020-2025)
 Table 61. Global Antibacterial (Drug) Resistance Sales (K Units) by Indication (2026-2031)
 Table 62. Global Antibacterial (Drug) Resistance Sales Market Share by Indication (2020-2025)
 Table 63. Global Antibacterial (Drug) Resistance Sales Market Share by Indication (2026-2031)
 Table 64. Global Antibacterial (Drug) Resistance Revenue (US$ Million) by Indication (2020-2025)
 Table 65. Global Antibacterial (Drug) Resistance Revenue (US$ Million) by Indication (2026-2031)
 Table 66. Global Antibacterial (Drug) Resistance Revenue Market Share by Indication (2020-2025)
 Table 67. Global Antibacterial (Drug) Resistance Revenue Market Share by Indication (2026-2031)
 Table 68. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Indication (2020-2025)
 Table 69. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Indication (2026-2031)
 Table 70. Melinta Therapeutics Company Information
 Table 71. Melinta Therapeutics Description and Business Overview
 Table 72. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Melinta Therapeutics Antibacterial (Drug) Resistance Product
 Table 74. Melinta Therapeutics Recent Developments/Updates
 Table 75. Allergan Company Information
 Table 76. Allergan Description and Business Overview
 Table 77. Allergan Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Allergan Antibacterial (Drug) Resistance Product
 Table 79. Allergan Recent Developments/Updates
 Table 80. Merck Company Information
 Table 81. Merck Description and Business Overview
 Table 82. Merck Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Merck Antibacterial (Drug) Resistance Product
 Table 84. Merck Recent Developments/Updates
 Table 85. Abbott Laboratories Company Information
 Table 86. Abbott Laboratories Description and Business Overview
 Table 87. Abbott Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Abbott Laboratories Antibacterial (Drug) Resistance Product
 Table 89. Abbott Laboratories Recent Developments/Updates
 Table 90. Pfizer Company Information
 Table 91. Pfizer Description and Business Overview
 Table 92. Pfizer Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Pfizer Antibacterial (Drug) Resistance Product
 Table 94. Pfizer Recent Developments/Updates
 Table 95. GSK Company Information
 Table 96. GSK Description and Business Overview
 Table 97. GSK Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. GSK Antibacterial (Drug) Resistance Product
 Table 99. GSK Recent Developments/Updates
 Table 100. PENDOPHARM Company Information
 Table 101. PENDOPHARM Description and Business Overview
 Table 102. PENDOPHARM Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. PENDOPHARM Antibacterial (Drug) Resistance Product
 Table 104. PENDOPHARM Recent Developments/Updates
 Table 105. Absynth Biologics Company Information
 Table 106. Absynth Biologics Description and Business Overview
 Table 107. Absynth Biologics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Absynth Biologics Antibacterial (Drug) Resistance Product
 Table 109. Absynth Biologics Recent Developments/Updates
 Table 110. Achaogen Company Information
 Table 111. Achaogen Description and Business Overview
 Table 112. Achaogen Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. Achaogen Antibacterial (Drug) Resistance Product
 Table 114. Achaogen Recent Developments/Updates
 Table 115. Acino Holdings Company Information
 Table 116. Acino Holdings Description and Business Overview
 Table 117. Acino Holdings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. Acino Holdings Antibacterial (Drug) Resistance Product
 Table 119. Acino Holdings Recent Developments/Updates
 Table 120. Aventis Pharma Company Information
 Table 121. Aventis Pharma Description and Business Overview
 Table 122. Aventis Pharma Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 123. Aventis Pharma Antibacterial (Drug) Resistance Product
 Table 124. Aventis Pharma Recent Developments/Updates
 Table 125. Austell Laboratories Company Information
 Table 126. Austell Laboratories Description and Business Overview
 Table 127. Austell Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 128. Austell Laboratories Antibacterial (Drug) Resistance Product
 Table 129. Austell Laboratories Recent Developments/Updates
 Table 130. Assembly Biosciences Company Information
 Table 131. Assembly Biosciences Description and Business Overview
 Table 132. Assembly Biosciences Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 133. Assembly Biosciences Antibacterial (Drug) Resistance Product
 Table 134. Assembly Biosciences Recent Developments/Updates
 Table 135. Arpida Company Information
 Table 136. Arpida Description and Business Overview
 Table 137. Arpida Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 138. Arpida Antibacterial (Drug) Resistance Product
 Table 139. Arpida Recent Developments/Updates
 Table 140. Demuris Company Information
 Table 141. Demuris Description and Business Overview
 Table 142. Demuris Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 143. Demuris Antibacterial (Drug) Resistance Product
 Table 144. Demuris Recent Developments/Updates
 Table 145. Evolva Holding Company Information
 Table 146. Evolva Holding Description and Business Overview
 Table 147. Evolva Holding Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 148. Evolva Holding Antibacterial (Drug) Resistance Product
 Table 149. Evolva Holding Recent Developments/Updates
 Table 150. ContraFect Company Information
 Table 151. ContraFect Description and Business Overview
 Table 152. ContraFect Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 153. ContraFect Antibacterial (Drug) Resistance Product
 Table 154. ContraFect Recent Developments/Updates
 Table 155. Cerexa Company Information
 Table 156. Cerexa Description and Business Overview
 Table 157. Cerexa Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 158. Cerexa Antibacterial (Drug) Resistance Product
 Table 159. Cerexa Recent Developments/Updates
 Table 160. InterMune Company Information
 Table 161. InterMune Description and Business Overview
 Table 162. InterMune Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 163. InterMune Antibacterial (Drug) Resistance Product
 Table 164. InterMune Recent Developments/Updates
 Table 165. Isis Pharmaceuticals Company Information
 Table 166. Isis Pharmaceuticals Description and Business Overview
 Table 167. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 168. Isis Pharmaceuticals Antibacterial (Drug) Resistance Product
 Table 169. Isis Pharmaceuticals Recent Developments/Updates
 Table 170. Lyndra Company Information
 Table 171. Lyndra Description and Business Overview
 Table 172. Lyndra Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 173. Lyndra Antibacterial (Drug) Resistance Product
 Table 174. Lyndra Recent Developments/Updates
 Table 175. Microbecide Company Information
 Table 176. Microbecide Description and Business Overview
 Table 177. Microbecide Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 178. Microbecide Antibacterial (Drug) Resistance Product
 Table 179. Microbecide Recent Developments/Updates
 Table 180. Morphochem Company Information
 Table 181. Morphochem Description and Business Overview
 Table 182. Morphochem Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 183. Morphochem Antibacterial (Drug) Resistance Product
 Table 184. Morphochem Recent Developments/Updates
 Table 185. Nabriva Therapeutics Company Information
 Table 186. Nabriva Therapeutics Description and Business Overview
 Table 187. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 188. Nabriva Therapeutics Antibacterial (Drug) Resistance Product
 Table 189. Nabriva Therapeutics Recent Developments/Updates
 Table 190. NanoSafe Coatings Company Information
 Table 191. NanoSafe Coatings Description and Business Overview
 Table 192. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 193. NanoSafe Coatings Antibacterial (Drug) Resistance Product
 Table 194. NanoSafe Coatings Recent Developments/Updates
 Table 195. Novexel Company Information
 Table 196. Novexel Description and Business Overview
 Table 197. Novexel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 198. Novexel Antibacterial (Drug) Resistance Product
 Table 199. Novexel Recent Developments/Updates
 Table 200. Osel Company Information
 Table 201. Osel Description and Business Overview
 Table 202. Osel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 203. Osel Antibacterial (Drug) Resistance Product
 Table 204. Osel Recent Developments/Updates
 Table 205. VenatoRx Pharmaceuticals Company Information
 Table 206. VenatoRx Pharmaceuticals Description and Business Overview
 Table 207. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 208. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product
 Table 209. VenatoRx Pharmaceuticals Recent Developments/Updates
 Table 210. AAIPharma Services Company Information
 Table 211. AAIPharma Services Description and Business Overview
 Table 212. AAIPharma Services Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 213. AAIPharma Services Antibacterial (Drug) Resistance Product
 Table 214. AAIPharma Services Recent Developments/Updates
 Table 215. ANTABIO Company Information
 Table 216. ANTABIO Description and Business Overview
 Table 217. ANTABIO Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 218. ANTABIO Antibacterial (Drug) Resistance Product
 Table 219. ANTABIO Recent Developments/Updates
 Table 220. Key Raw Materials Lists
 Table 221. Raw Materials Key Suppliers Lists
 Table 222. Antibacterial (Drug) Resistance Distributors List
 Table 223. Antibacterial (Drug) Resistance Customers List
 Table 224. Antibacterial (Drug) Resistance Market Trends
 Table 225. Antibacterial (Drug) Resistance Market Drivers
 Table 226. Antibacterial (Drug) Resistance Market Challenges
 Table 227. Antibacterial (Drug) Resistance Market Restraints
 Table 228. Research Programs/Design for This Report
 Table 229. Key Data Information from Secondary Sources
 Table 230. Key Data Information from Primary Sources
 Table 231. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Antibacterial (Drug) Resistance
 Figure 2. Global Antibacterial (Drug) Resistance Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Antibacterial (Drug) Resistance Market Share by Type: 2024 & 2031
 Figure 4. Telavancin (Vibativ) Product Picture
 Figure 5. Ceftaroline Fosamil (Teflaro/ Zinforo) Product Picture
 Figure 6. Fidaxomicin (Dificid / Dificlir) Product Picture
 Figure 7. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Product Picture
 Figure 8. Dalbavancin (Dalvance/ Xydalba) Product Picture
 Figure 9. Tedizolid Phosphate (Sivextro) Product Picture
 Figure 10. Oritavancin (Orbactiv/ Nuvocid) Product Picture
 Figure 11. Ceftolozane-Tazobactam (Zerbaxa) Product Picture
 Figure 12. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Product Picture
 Figure 13. Global Antibacterial (Drug) Resistance Market Value by Indication (2020-2031) & (US$ Million)
 Figure 14. Global Antibacterial (Drug) Resistance Market Share by Indication: 2024 & 2031
 Figure 15. Complicated Urinary Tract Infection (CUTI)
 Figure 16. Complicated Intra-Abdominal Infections (CIAI)
 Figure 17. Blood Stream Infections (BSI)
 Figure 18. Clostridium Difficile Infections (CDI)
 Figure 19. Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
 Figure 20. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
 Figure 21. Community Acquired Bacterial Pneumonia (CABP)
 Figure 22. Global Antibacterial (Drug) Resistance Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 23. Global Antibacterial (Drug) Resistance Market Size (2020-2031) & (US$ Million)
 Figure 24. Global Antibacterial (Drug) Resistance Sales (2020-2031) & (K Units)
 Figure 25. Global Antibacterial (Drug) Resistance Average Price (USD/Unit) & (2020-2031)
 Figure 26. Antibacterial (Drug) Resistance Report Years Considered
 Figure 27. Antibacterial (Drug) Resistance Sales Share by Manufacturers in 2024
 Figure 28. Global Antibacterial (Drug) Resistance Revenue Share by Manufacturers in 2024
 Figure 29. Global 5 and 10 Largest Antibacterial (Drug) Resistance Players: Market Share by Revenue in Antibacterial (Drug) Resistance in 2024
 Figure 30. Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 31. Global Antibacterial (Drug) Resistance Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 32. North America Antibacterial (Drug) Resistance Sales Market Share by Country (2020-2031)
 Figure 33. North America Antibacterial (Drug) Resistance Revenue Market Share by Country (2020-2031)
 Figure 34. U.S. Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Canada Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Europe Antibacterial (Drug) Resistance Sales Market Share by Country (2020-2031)
 Figure 37. Europe Antibacterial (Drug) Resistance Revenue Market Share by Country (2020-2031)
 Figure 38. Germany Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. France Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. U.K. Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Italy Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Russia Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Region (2020-2031)
 Figure 44. Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Region (2020-2031)
 Figure 45. China Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Japan Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. South Korea Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. India Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Australia Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. China Taiwan Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Indonesia Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Thailand Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Malaysia Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Latin America Antibacterial (Drug) Resistance Sales Market Share by Country (2020-2031)
 Figure 55. Latin America Antibacterial (Drug) Resistance Revenue Market Share by Country (2020-2031)
 Figure 56. Mexico Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Brazil Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Argentina Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Country (2020-2031)
 Figure 60. Middle East and Africa Antibacterial (Drug) Resistance Revenue Market Share by Country (2020-2031)
 Figure 61. Turkey Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 62. Saudi Arabia Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 63. UAE Antibacterial (Drug) Resistance Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 64. Global Sales Market Share of Antibacterial (Drug) Resistance by Type (2020-2031)
 Figure 65. Global Revenue Market Share of Antibacterial (Drug) Resistance by Type (2020-2031)
 Figure 66. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Type (2020-2031)
 Figure 67. Global Sales Market Share of Antibacterial (Drug) Resistance by Indication (2020-2031)
 Figure 68. Global Revenue Market Share of Antibacterial (Drug) Resistance by Indication (2020-2031)
 Figure 69. Global Antibacterial (Drug) Resistance Price (USD/Unit) by Indication (2020-2031)
 Figure 70. Antibacterial (Drug) Resistance Value Chain
 Figure 71. Channels of Distribution (Direct Vs Distribution)
 Figure 72. Bottom-up and Top-down Approaches for This Report
 Figure 73. Data Triangulation
 Figure 74. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Antibiotic Resistance Biomarkers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antibiotic Resistance Market Insights Forecast to 2030
Multidrug Resistant Bacteria Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Anti Microbial Resistance Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antiviral Drug Resistance Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pets Antibiotic Treatment Solutions Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antimicrobial Resistance Surveillance Market Research Report 2024
Antimicrobial Susceptibility Test Market
Global Children s Drug Resistance Testing Market Research Report 2024
Antibiotic Resistance Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Multiple Drug Resistance Bacterial Infection Treatment Market Insights Forecast to 2030
Global Pediatric Antibiotics Market Research Report 2024
Anti Infective Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
MRSA Antibiotics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antibiotic Susceptibility Testing Market
Anti Infective Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drug Resistant Tuberculosis Treatment Market Research Report 2025
Bacterial Identification and Drug Sensitivity Testing Market
Antibiotics Active Pharmaceutical Ingredient API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antibacterial Paint Market Research Report 2025

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions